

9/15/2005 IDS

EXPRESS MAIL NO. EV 531 712 866 US
JC1763d PCT/PTO 15 SEP 2005
Sheet 1 of 1LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11340-007-999

APPLICATION NO.
To Be Assigned(National Stage of
PCT/EP02/04303, filed
April 18, 2002)

APPLICANT

Ensoli

FILING DATE

On Even Date Herewith

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,506,555	01/14/03	Andre et al.	=====	=====	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
	B01	WO 99/63998	12/16/99	PCT (with English abstract) <i>abstract only</i>	=====	=====			
	B02	WO 00/33654	06/15/00	PCT	=====	=====			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Andre et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13120-4.
	C02	Berthelot et al. Dramatic cutaneous psoriasis improvement in a patient with the human immunodeficiency virus treated with 2',3'-dideoxy,3'-thiacytidine [correction of 2',3'-dideoxycytidine] and ritonavir. Arch Dermatol. 1997 Apr;133(4):531.
	C03	Conant et al. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS. 1997 Aug;11(10):1300-1.
	C04	Sgadari et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002 Mar;8(3):225-32.
	C05	International Search Report for International Application No. PCT/EP02/04303.

EXAMINER	/Nicole Kinsey/	DATE CONSIDERED	03/26/2008
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NK/

NYID: A575078.1